As featured in
Testosterone delivers changes many trans men have waited years for — and for those who carry the genetics for it, one unwanted passenger can ride along: male-pattern hair loss. It’s the least-discussed side effect of masculinising hormone therapy, sometimes searched as FTM hair loss, and the silence serves nobody, because it is predictable, monitorable and treatable — best managed when someone is watching from early on rather than reacting three years in.
This page gives it the straight treatment: your actual risk, what to watch for, and how treatment decisions get made around your masculinisation goals — not against them. Hair GP treats your hair alongside your testosterone therapy; your regimen itself stays with your GIC, endocrinologist or prescriber, exactly where it should be.
Why testosterone can thin scalp hair — and who it happens to
The same biology that runs pattern loss in cis men now runs in you: testosterone converts to dihydrotestosterone (DHT), and follicles genetically programmed to be sensitive respond by miniaturising — each cycle shorter and finer, temples and crown first. The genetics are the point: testosterone doesn’t cause hair loss in everyone, it reveals susceptibility where it exists, which is why the best single predictor is pattern loss in your blood relatives of any gender. Dose and duration matter less than people assume once levels are in the standard masculinising range — susceptible follicles respond to the presence of DHT, not the excess of it. What this means practically: if the family history is there, assume the possibility, watch from early, and know that watching is not helplessness — every effective treatment works better started early.
The early shed vs. the real thing — telling them apart
Two different events get confused, with opposite meanings. A diffuse shed in the first months on testosterone — more hairs everywhere, no particular pattern — is usually telogen effluvium, the temporary reset any major hormonal shift can trigger; it settles as your cycle re-establishes, and our starting-hormones shedding guide covers it in full. Pattern loss announces itself differently: gradual, located, cumulative — temples pulling back, the crown thinning, a change your barber notices across months rather than your pillow announcing overnight. Under the dermatoscope the two are unmistakable (uniform shedding versus miniaturising follicles in the male pattern), which is why one baseline examination early in your time on T is the single highest-value monitoring move: it gives every future check something objective to compare against.
| What you’re seeing | Most likely | The move |
|---|---|---|
| Diffuse shedding, first 2–6 months on T | Reset shed (telogen effluvium) | Reassurance + monitoring; settles within months |
| Temples/crown gradually thinning, year 1–5 | Testosterone-revealed pattern loss | Examination, then treatment matched to your goals |
| Thinning + strong family history of baldness | Higher-risk pattern loss: worth acting early | Baseline trichoscopy now; low threshold for starting minoxidil |
| Shedding that never settles, no pattern | Something else: iron, thyroid, telogen drivers | Blood panel read for hair |
Treatment that respects your masculinisation — including the finasteride question, honestly
Minoxidil first, and without complication: topical or low-dose oral, it stimulates follicles directly, touches nothing hormonal, and changes nothing about your masculinisation — for most trans men with early pattern loss it’s the obvious opening move, and often enough alone. Finasteride is the nuanced one, and you deserve the nuance rather than a slogan. It works by blocking the conversion of testosterone to DHT — but DHT is also one of the drivers of masculinisation itself, contributing particularly to facial and body hair development. Blocking it early in transition can blunt changes you’re actively waiting for; further in, once those changes are established, the trade-off calculus shifts. There is no universal answer: there is your timeline, your priorities — some men rank the beard above the hairline, some the reverse, both are right — and a decision made deliberately, ideally with your prescriber in the loop, which is exactly the letter we write. What we won’t do is hand out finasteride as a reflex or withhold it as a rule; the whole point of specialist care is that the decision fits you. Where loss is established and stable, FUE transplantation is on the table too, on the same honest candidacy terms as for anyone.
A sensible monitoring protocol (what we actually set up)
For a trans man with family-history risk, the protective structure looks like this — and none of it slows your transition. Baseline within the first year on T: trichoscopy mapping of temples, crown and parting, plus standardised photographs; twenty minutes that make every future comparison objective. An annual photo-and-scope review (sooner if you notice change): miniaturisation shows under magnification one to two years before mirrors catch it, and that head start is the whole game. An agreed trigger for treatment: not “when it looks bad” but a defined change from baseline — because gradual loss recalibrates what you think looks normal, and objective triggers beat drifting ones. Escalation pre-planned: minoxidil at first confirmed change; the finasteride conversation staged for where your masculinisation goals sit by then. Men who set this up almost never face the bad version of this condition, because the bad version is mostly a story about late detection.
Bringing your prescriber in: how the conversation works
If treatment decisions touch your hormone therapy — the finasteride question chief among them — the letter we write your GIC, endocrinologist or GP does specific work: it documents what examination found, sets out the options considered with their trade-offs against your stated masculinisation priorities, and makes a recommendation while explicitly leaving GAHT-side judgements to the team that owns them. Prescribers respond well to this structure because it respects the boundary — we’re not adjusting your testosterone or second-guessing your regimen; we’re adding follicle-level expertise to their picture. If your care is fragmented (a common reality — private prescriber here, GP shared-care there), tell us who should receive what; patients with complicated arrangements are our normal, not our exception.
What patients say
Not only did I come away with a solid treatment plan for my hair, Amy also gave me loads of recommendations on managing PMOS and looking after my general health.
I suffer with female pattern hair loss and I'm in perimenopause. Dr Amy was so kind and caring, and had a holistic view looking at all blood tests, hormones and an inspection of my hair and scalp under the microscope. I have a clear treatment plan…
What happens at your consultation
Fifty minutes with Dr Amy: your history — family pattern, time on T, what you’ve noticed and when — examination under magnification that distinguishes reset shedding from true pattern change and grades where you are, bloods where they would genuinely alter the plan, and a written strategy built around your stated goals: which treatment, started when, monitored how, with photographs as the objective record. If the finasteride conversation is relevant, you’ll get it straight — mechanism, trade-offs, timing — and a letter for your prescribing team if you want them involved in the decision. Not sure any of this is worth an appointment yet? Message the clinic on WhatsApp with questions about what the consultation involves; plenty of people who do come are told watchful waiting is fine for now, and that is a perfectly good outcome.
No: it reveals susceptibility rather than creating it. Testosterone converts to DHT, and only follicles genetically sensitive to DHT miniaturise in response; without that genetic programming, decades on T leave scalp hair untouched. The strongest predictor is family history of pattern baldness in blood relatives of any gender. If that history exists, the sensible posture isn’t fear: it’s a baseline examination early on and a low threshold for starting treatment, because everything that works, works best early.
When it happens at all, pattern loss most commonly declares itself within the first one to five years: gradual temple recession and crown thinning rather than sudden shedding. Distinguish this from the diffuse shed some people get two to six months after starting T: that’s usually telogen effluvium, the temporary reset that follows any major hormonal shift, and it settles on its own. The two look completely different under a dermatoscope, which is why one early baseline examination makes every later question easy to answer.
You can: whether you should is the genuinely individual part. Finasteride blocks the conversion of testosterone to DHT, protecting DHT-sensitive scalp follicles; but DHT also contributes to masculinisation, particularly facial and body hair development, so blocking it early in transition can slow changes you’re waiting for. Further into transition, with those changes established, the trade-off often looks different. It’s a decision to make deliberately (your priorities, your timeline, ideally with your prescriber informed), and that structured conversation is exactly what the consultation provides. Meanwhile minoxidil, which touches no hormones, is very often the right first move.
Minoxidil, the usual first-line, affects nothing hormonal: it stimulates follicles directly and leaves your masculinisation exactly as your testosterone therapy is building it. The only mainstream treatment with a masculinisation trade-off is finasteride, because DHT sits on both sides of the ledger; that’s why it gets a proper individualised discussion rather than a default. Nothing we recommend alters your testosterone regimen itself, which stays entirely with your prescriber.
That’s a question for your prescriber rather than a hair clinic, and it’s usually the wrong lever anyway. Within standard masculinising ranges, susceptible follicles respond to DHT’s presence more than its quantity, so dose reductions typically trade away wellbeing and masculinisation for little scalp benefit. The better tools work at the follicle: minoxidil support, the finasteride conversation where appropriate, and early monitoring. If anything in your hormonal picture seems genuinely relevant to your hair, we put it in a letter to your prescribing team and leave GAHT decisions where they belong.
Caught early, substantially: miniaturised follicles respond well to treatment, and minoxidil regrows measurable hair in most people who start before follicles are lost. Established bald areas follow the same rules as any pattern loss: medication protects and partially recovers, and FUE transplantation permanently restores where medicine can’t, subject to honest candidacy assessment. The arithmetic favours early action strongly, which is why ‘watch it with a baseline’ beats ‘wait and see’: the first gives you an early warning system; the second gives you regret.
